• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Wants Talk Psychotherapy but Cannot Talk: EMDR for Post-stroke Depression with Expressive Aphasia
CONCLUSION This is the first reported case demonstrating that EMDR can be effective for depression, even in those with severe expressive aphasia. In our case, there was no reluctance to disclose information, simply a neurological inability to do so. Through preparation, patience, perseverance, and plasticity (clinician flexibility, though perhaps also neuroplasticity), the patient’s PSD gradually improved, and she was able to reinvent her life within her limitations. ACKNOWLEDGMENTS The authors gratefully acknowledge Eugene Schwartz, E.C. Hurley, and Mark Hubner for providing consultation during patient care. REFERENCES ...
Source: Innovations in Clinical Neuroscience - February 1, 2018 Category: Neuroscience Authors: ICN Online Editor Tags: Case Report Current Issue Neurologic Systems and Symptoms Neurology Psychotherapy Stroke aphasia depression EMDR Source Type: research

Cardiovascular adverse events in the drug ‐development program of bupropion for smoking cessation: A systematic retrospective adjudication effort
Conclusions CV events in bupropion clinical trials for smoking cessation were uncommon, with no observed increase among subjects assigned to bupropion vs placebo. However, this effort was limited by a paucity of quality data.
Source: Clinical Cardiology - June 12, 2017 Category: Cardiology Authors: Jessie Kittle, Renato D. Lopes, Mingyan Huang, Marsha L. Marquess, Matthew D. Wilson, John Ascher, Alok Krishen, Vic Hasselblad, Brad J. Kolls, Matthew T. Roe, Darren K. McGuire, Stuart D. Russell, Kenneth W. Mahaffey Tags: CLINICAL INVESTIGATIONS Source Type: research

How to Quit Smoking
By Stacy Simon Tobacco use remains the single largest preventable cause of disease and premature death in the United States. Since the release of the Surgeon General’s Report on Smoking and Health 50 years ago, there have been 20 million deaths due to tobacco. Almost half the deaths from 12 different types of cancer combined – including lung, voice box, throat, esophagus, and bladder cancers – are attributable to cigarette smoking alone. In addition to cancer, smoking greatly increases the risk of debilitating long-term lung diseases like emphysema and chronic bronchitis. It also raises the risk for heart...
Source: American Cancer Society :: News and Features - November 16, 2016 Category: Cancer & Oncology Tags: Smoking/Tobacco Source Type: news

Study: Nicotine Patch Works as Well as Chantix to Help Quit Smoking
This study confirms that FDA-approved medications are effective in helping smokers quit,” said Lee Westmaas, PhD, American Cancer Society director of tobacco control research. “Smokers should seriously consider using medications if they are finding it difficult to quit without any help. The most effective approach to quitting is using medications in combination with counseling such as from a quit-line.”RESOURCES: How to Quit Smoking Quit-smoking medicationsResearch shows that using a medication to help you quit smoking can double your chances of being successful.The US Food and Drug Administration (...
Source: American Cancer Society :: News and Features - February 2, 2016 Category: Cancer & Oncology Tags: Smoking/Tobacco Source Type: news

Annual budgetary impact of varenicline as part of a smoking cessation strategy in Greece
Conclusions: Varenicline reimbursement may represent a balanced strategy from a budget impact perspective in Greece even taking into account hospital resource utilization only.
Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Katsaounou, P., Bilitou, A., Tsekouras, V. Tags: 6.3 Tobacco, Smoking Control and Health Education Source Type: research

Cardiovascular and mortality risks in older Medicare patients treated with varenicline or bupropion for smoking cessation: an observational cohort study
ConclusionCardiovascular and mortality risks were not increased in older patients treated with varenicline compared with bupropion for smoking cessation. A potential increase in the risk of stroke with varenicline could not be excluded. Treatment persistence with either drug was low. Published 2014. This article is a U.S. Government work and is in the public domain in the USA.
Source: Pharmacoepidemiology and Drug Safety - July 5, 2014 Category: Drugs & Pharmacology Authors: David J. Graham, Kunthel By, Stephen McKean, Andrew Mosholder, Cynthia Kornegay, Judith A. Racoosin, Jessica Young, Mark Levenson, Thomas E. MaCurdy, Chris Worrall, Jeffrey A. Kelman Tags: Original Report Source Type: research

'No serious heart risks' linked to smoking cessation therapies
The American Heart Association claims that three different types of smoking cessation therapies do not pose serious heart risks, quashing concerns that certain products may increase the risks of heart attack, stroke or heart-related death.Researchers looked at the results of 63 clinical trials involving 30, 508 people who were quitting smoking using either nicotine replacement gums and patches, the nicotine addiction treatment varenicline (Chantix), or taking the antidepressant bupropion (Wellbutrin), which can reduce cravings and other unwanted withdrawal effects.
Source: Health News from Medical News Today - December 13, 2013 Category: Consumer Health News Tags: Smoking / Quit Smoking Source Type: news